Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer
Shira Sherman(Dana-Farber Cancer Institute), Rinath Jeselsohn(Harvard University)
Cited by 10
Related Papers
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer
|Clinical Cancer Research|2024|34
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
|Cancer Research|2023|15
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer
|npj Breast Cancer|2024|4